Tilray Medical Launches Redecan Cannabis Brand In Australia | Where to order Skittles Moonrock online

NEW YORK, Sept. 18, 2024 – PRESS RELEASE – Tilray Medical announced the launch of Redecan EU GMP certified medical cannabis products. Tilray Medical is a division of Tilray Brands Inc. and a global leader of medical cannabis. It empowers the therapeutic alliance between health care providers and patients to make informed, individualized health decisions.

Denise Faltischek is the chief strategy officer at Tilray Brands and head of International. She said: “The launch in Australia of Redecan premium cannabis brand is another milestone for Tilray Medical as we relentlessly pursued our vision to make high-quality medical marijuana products accessible to patients around the world.” The launch of Redecan expands our medical cannabis offerings alongside our current Tilray, Broken Coast and Tilray Brands offerings. We continue our mission to empower patients and health care professionals to find optimal therapeutic solutions.

Jonathan Trodden said, “We’re proud to launch Redecan here in Australia and further strengthen the ongoing commitment we have to provide patients with a constant, accessible supply of premium-quality medical cannabis.”

Redecan products for medical cannabis patients are now available in Australia.

• Redecan PCTHC28 Purple Churro 15 grams
• Redecan SA-THC28 Space Age cake – 15 grams

Tilray is one of the world’s leading providers of EU GMP-certified medical cannabis for patients, doctors, pharmacies, hospitals and governments. It offers a complete portfolio of THC- and CBD-based products in over 20 countries.

Tilray, in support of its mission, has supported medical trials worldwide that have studied the efficacy and safety of medical cannabis for indications such as fibromyalgia and cancer-induced nausea and vomit, HIV, essential-tremor, breast-cancer disorders, post-traumatic-stress disorder, and alcohol use disorders.

Get curated news on YOUR industry.

Enter your email address to receive our newsletter.